JIXING PHARMACEUTICALS
Jixing Pharmaceuticals develops innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.
JIXING PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.jixingbio.com
Total Employee:
11+
Status:
Active
Contact:
+86-021-80311808
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Current Employees Featured
Investors List
RTW Investments LLC
RTW Investments LLC investment in Series B - Jixing Pharmaceuticals
Official Site Inspections
http://www.jixingbio.com
- Host name: 40.73.39.95
- IP address: 40.73.39.95
- Location: Beijing China
- Latitude: 39.9288
- Longitude: 116.3889
- Timezone: Asia/Shanghai
More informations about "Jixing Pharmaceuticals"
Jixing Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected] Phone Number +86-021-80311808 Jixing Pharmaceuticals is a global biotechnology company that develops and commercializes novel therapeutics to treat medical needs in cardiovascular …See details»
JIXING ANNOUNCES THE APPOINTMENT OF KUN WU …
Mar 31, 2022 Kun brings strong biopharmaceutical expertise and will be responsible to build JIXING’s commercial strategy & organization SHANGHAI, China, March 31, 2022 – Ji Xing Pharmaceuticals Limited ...See details»
CORXEL Pharmaceuticals | 领英 - 领英 (中国)
CORXEL Pharmaceuticals | 在领英上有 1,350 位关注者。Our mission is to develop innovative cardiometabolic therapies globally. | CORXEL, formerly named Ji Xing Pharmaceuticals, is a leading biotech company headquartered …See details»
Ji Xing Pharmaceuticals Co., Ltd. - synapse.zhihuiya.com
Objectives: Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic …See details»
Jixing Pharmaceuticals - Crunchbase Company Profile & Funding
Jixing Pharmaceuticals is a biotechnology company that develops science and medicines for underserved patients.See details»
致力于在全球开发最前沿的针对心血管代谢类疾病的创新疗法
箕星是一家生物科技公司，致力于将创新科学和药物带给罹患严重危及生命健康疾病的心血管代谢患者。See details»
Cytokinetics and JI XING Announce Expansion of Collaboration to …
Dec 20, 2021 JI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure Cytokinetics to Receive $70 Million in Committed Capital;Up to an Additional …See details»
JIXINGAcquiredACardiovascularAssetForGlobalDevelopment
Shanghai, China, February 6th, 2023 – Ji Xing Pharmaceuticals Limited (JIXING), a biopharmaceutical company committed to bringing innovative medicines to underserved …See details»
JIXING - Company Profile - Tracxn
Oct 22, 2024 What are the most recent funding rounds of JIXING? Its latest funding round was a Series D round on Jan 08, 2024 for $127M. 2 investors participated in its latest round, lead by …See details»
CORXEL – Developing the next generation cardiovascular …
CORXEL is a leading biopharmaceutical company headquartered in US and China committed to bringing innovative science and medicines to underserved patients with serious and life …See details»
JIXING and WuXi STA Announce Strategic Partnership Agreement
Nov 6, 2023 As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions …See details»
Ji Xing appoints Wu Kun as the Chief Commercial Officer
Apr 2, 2022 “I am very excited to join JIXING and look forward to working with the leadership team to build the company’s commercial organization,” said Kun Wu, newly appointed Chief …See details»
Hovione and JIXING Announce an Exclusive Global License …
May 9, 2022 For further information about JIXING, please visit www.jixingbio.com About Hovione: Hovione is an international company with over 60 years of experience as a Contract …See details»
箕星从渤健收购用于治疗急性缺血性脑卒中的BIIB131医药新闻-ByD…
⌈ByDrug医药新闻摘要⌋ 2024-01-11 17:30，箕星药业：中国上海--2024 年 1 月 11 日—箕星药业（下文简称“箕星”），一家致力于为罹患严重危及生命健康的疾病的患者提供创新药物且处于 …See details»
Bayer and RTW Investments lead Series D financing in Chinese …
Jan 6, 2024 Berlin, Germany, New York City, USA and Shanghai, China, January 6, 2024 – Bayer and RTW Investments, LP (“RTW”) today announced an equity investment into Ji Xing …See details»
箕星宣布Aficamten与美托洛尔对比治疗症状性梗阻性肥厚型心肌 …
Oct 18, 2023 更多信息请访问www.jixingbio.com 和“箕星药业”微信公众号。 关于Cytokinetics Cytokinetics是一家专业于心血管新药研发后期的生物制药公司，致力于同类首创肌肉激活剂 …See details»
箕星宣布aficamten在中国获得突破性治疗药物认定医药新闻-ByDru…
⌈ByDrug医药新闻摘要⌋ 2022-02-16 14:48，箕星药业：基于REDWOOD-HCM和中国1期临床研究结果，国家药品监督管理局授予治疗症状性梗阻性肥厚型心肌病的突破性治疗药物认定。 …See details»
Cytokinetics and JI XING Announce Expansion of Collaboration to …
Aug 29, 2013 JI XING to Develop and Commercialize Novel Cardiac Myosin Activator in Patients with Heart Failure. Cytokinetics to Receive $70 Million in Committed Capital; Up to an …See details»
Firm Advises JIXING on Acquisition of BIIB131 from Biogen
On January 11, 2024, Ji Xing Pharmaceuticals (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved patients with serious and …See details»